Hans Bjarke Rahr

Dr. Hans Bjarke Rahr

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2010 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HNHans J. Nielsen
Hans J. Nielsen
NBNils Brünner
Nils Brünner
LJLars N. Jorgensen
Lars N. Jorgensen
JOJesper Olsen
Jesper Olsen
HRHans Bjarke Rahr
Hans Bjarke Rahr
TGThe Danish Colorectal Cancer Cooperative Group
The Danish Colorectal Cancer Cooperative Group
Objective. The combination of plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) and carcinoembryonic antigen (CEA) may be valuable biomarkers for early detection of colorectal cancer (CRC). A prospective, population based study was performed to validate this hypothesis. Material and methods. Individuals (n = 4509) referred for large bowel endoscopy due to symptoms of CRC were prospectively included. Baseline data and concurrent diseases were recorded. The primary endpoint was detection of CRC and findings at examinations were recorded using International Classification of Diseases-10 codes. Plasma was obtained before endoscopy and TIMP-1 and CEA levels were determined after the inclusion of all individuals. Results. Findings were based on sigmoidoscopy in 1766 and colonoscopy in 2743 individuals. Colon cancer (CC) was detected in 184 and rectal cancer in 110 individuals. Ten individuals with other cancers, 856 with adenomas and 1176 with non-neoplastic findings were also detected. The biomarker levels were increased in a variety of diseases including CRC compared to individuals without any findings at endoscopy. A multivariable analysis demonstrated that both markers were significant and independent detectors of CRC. Combining both biomarkers, independent contributions from each (TIMP-1, odds ratio (OR) = 1.8 (95% confidence interval (CI): 1.4–2.2), p < 0.0001; CEA < 5 ng/ml, OR = 1.6, 1.3–1.9, or ≥5 ng/ml, OR = 2.3, 95% CI: 1.9–2.7 (p < 0.0001)) were obtained. Subgroup analysis of individuals examined by colonoscopy with CC as the endpoint showed that combining both biomarkers, independent contributions from each (TIMP-1, OR = 2.5, 95% CI: 1.8–3.4, p < 0.0001; CEA < 5 ng/ml, OR = 1.4, 95% CI: 1.1–1.8, and CEA ≥ 5 ng/ml, OR = 2.3, 95% CI: 1.8–3.0 (p < 0.0001)) were obtained. Conclusions. This prospective validation study supports the use of the combination of plasma TIMP-1 and CEA protein measurements as a potential aid in early detection of CRC and specifically of CC.

1 March 2015 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JJJulia Sidenius Johansen
Julia Sidenius Johansen
ICIb J. Christensen
Ib J. Christensen
LJLars N. Jorgensen
Lars N. Jorgensen
JOJesper Olsen
Jesper Olsen
HRHans Bjarke Rahr
Hans Bjarke Rahr
HNHans J. Nielsen
Hans J. Nielsen
The aim of the present study was to test the hypothesis that high serum YKL-40 associates with colorectal cancer in subjects at risk of colorectal cancer. We measured serum YKL-40 in a prospective study of 4,496 Danish subjects [2,064 men, 2,432 women, median age 61 years (range, 18–97)] referred to endoscopy due to symptoms or other risk factors for colorectal cancer. Blood samples were collected just before large bowel endoscopy. Serum YKL-40 was determined by ELISA. Serum YKL-40 was higher (P < 0.0001, unadjusted for confounding covariates) in subjects diagnosed with colon cancer (median 126 μg/L, 25%–75%: 80–206 μg/L) and rectal cancer (104, 72–204 μg/L) compared with subjects with adenoma (84, 53–154 μg/L), other nonmalignant findings (79, 49–138 μg/L), and no findings (62, 41–109 μg/L). Serum YKL-40 independently predicted colorectal cancer [OR, 1.53; 95% confidence interval (CI), 1.40–1.67; AUC = 0.68, P < 0.0001]. Restricting the analysis to subjects with no comorbidity increased the OR for serum YKL-40 to predict colorectal cancer (OR, 1.82; 1.58–2.08; AUC = 0.73, P < 0.0001). Combining serum YKL-40 and CEA demonstrated that both were significant [(YKL-40, OR, 1.27; 95% CI, 1.16–1.40); (CEA, OR, 1.92; 1.75–2.10; AUC = 0.75, P < 0.0001; OR for a 2-fold difference in marker level)]. Multivariable analysis (YKL-40, CEA, age, gender, body mass index, and center) showed that serum YKL-40 was a predictor for colorectal cancer in individuals without comorbidity (OR, 1.25; 95% CI, 1.05–1.40; P = 0.012), whereas this was not the case for those with comorbidity (OR, 0.98; 95% CI, 0.84–1.14; P = 0.80). In conclusion, high serum YKL-40 in subjects suspected of colorectal cancer and without comorbidity associates with colorectal cancer. Determination of serum YKL-40 may be useful in combination with other biomarkers in risk assessment for colorectal cancer. Cancer Epidemiol Biomarkers Prev; 24(3); 621–6. ©2015 AACR.

1 June 2017 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MLMette Bach Larsen
Mette Bach Larsen
EMEllen M Mikkelsen
Ellen M Mikkelsen
MRMorten Rasmussen
Morten Rasmussen
LFLennart Friis-Hansen
Lennart Friis-Hansen
AOAnders U Ovesen
Anders U Ovesen
BABerit Andersen
Berit Andersen
Introduction: Fecal occult blood tests are recommended for colorectal cancer (CRC) screening in Europe. Recently, the fecal immunochemical test (FIT) has come into use. Sociodemographic differences between participants and nonparticipants may be less pronounced when using FIT as there are no preceding dietary restrictions and only one specimen is required. The aim of this study was to examine the associations between sociodemographic characteristics and nonparticipation for both genders, with special emphasis on those who actively unsubscribe from the program. Methods: The study was a national, register-based, cross-sectional study among men and women randomized to be invited to participate in the prevalence round of the Danish CRC screening program between March 1 and December 31, 2014. Prevalence ratios (PRs) were used to quantify the association between sociodemographic characteristics and nonparticipation (including active nonparticipation). PRs were assessed using Poisson regression with robust error variance. Results: The likelihood of being a nonparticipant was highest in the younger part of the population; however, for women, the association across age groups was U-shaped. Female immigrants were more likely to be nonparticipants. Living alone, being on social welfare, and having lower income were factors that were associated with nonparticipation among both men and women. For both men and women, there was a U-shaped association between education and nonparticipation. For both men and women, the likelihood of active nonparticipation rose with age; it was lowest among non-western immigrants and highest among social welfare recipients. Conclusion: Social inequality in screening uptake was evident among both men and women in the Danish CRC screening program, even though the program is free of charge and the screening kit is based on FIT and mailed directly to the individuals. Interventions are needed to bridge this gap if CRC screening is to avoid aggravating existing inequalities in CRC-related morbidity and mortality.

13 February 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Søren Rafael RafaelsenSøren Rafael Rafaelsen
Søren Rafael Rafaelsen
CDClaus Dam
Claus Dam
CVChris Vagn-Hansen
Chris Vagn-Hansen
JMJakob Møller
Jakob Møller
HRHans Bjarke Rahr
Hans Bjarke Rahr
Malene Roland Vils PedersenMalene Roland Vils Pedersen
Malene Roland Vils Pedersen
(1) Background: Computer tomography (CT) scanning is currently the standard method for staging of colon cancer; however, the CT based preoperative local staging is far from optimal. The purpose of this study was to investigate the sensitivity and specificity of magnetic resonance imaging (MRI) compared to CT in the T- and N-staging of colon cancer. (2) Methods: Patients underwent a standard contrast-enhanced CT examination. For the abdominal MRI scan, a 3 Tesla unit was used, including diffusion weighted imaging (DWI). Experienced radiologists reported the CT and MRI scans blinded to each other and the endpoint of the pathological report. (3) Results: From 2018 to 2021, 134 patients received CT and MRI scans. CT identified 118 of the 134 tumors, whereas MRI identified all tumors. For discriminating between stage T3ab and T3cd, the sensitivity of CT was 51.1% and of MRI 80.0% (p = 0.02). CT and MRI showed a sensitivity of 21.4% and 46.4% in detecting pT4 tumors and a specificity of 79.0% and 85.0%, respectively. (4) Conclusion: Compared to CT, the sensitivity of MRI was statistically significantly higher in staging advanced T3cd and T4 tumors. MRI has the potential to be used in the treatment planning of colon cancer.